Severe hypoxemic respiratory failure: Part 2-nonventilatory strategies

Chest

Volumn 137, Issue 6, 2010, Pages 1437-1448

  Raoof, Suhail ^a   Goulet, Keith ^b   Esan, Adebayo ^a   Hess, Dean R ^c   Sessler, Curtis N ^b  

^a NEW YORK METHODIST HOSPITAL   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALMITRINE; AMINOPHYLLINE; CORTICOSTEROID; DOBUTAMINE; DOPAMINE; GAMMA LINOLENIC ACID; GLYCERYL TRINITRATE; HYDRALAZINE; ICOSAPENTAENOIC ACID; ILOPROST; ISOPRENALINE; METHYLPREDNISOLONE; NEUROMUSCULAR BLOCKING AGENT; NIFEDIPINE; NITRIC OXIDE; NITROPRUSSIDE SODIUM; PHENYLEPHRINE; PLACEBO; PROSTACYCLIN; PROSTAGLANDIN E1; SALBUTAMOL; STEROID; UNIPROST; VASOACTIVE AGENT; VASODILATOR AGENT;

ADULT RESPIRATORY DISTRESS SYNDROME; ARTIFICIAL VENTILATION; BODY POSITION; BODY POSTURE; CLINICAL TRIAL; CONSERVATIVE TREATMENT; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DIET SUPPLEMENTATION; DISEASE SEVERITY; DRUG COST; DRUG DOSE INCREASE; DRUG HALF LIFE; DRUG MECHANISM; EXTRACORPOREAL OXYGENATION; FLUID THERAPY; GAS EXCHANGE; GENERAL CONDITION IMPROVEMENT; HEMODYNAMICS; HUMAN; HYDROSTATIC PRESSURE; HYPOTENSION; HYPOVENTILATION; HYPOXEMIA; LENGTH OF STAY; LUNG BLOOD FLOW; LUNG VASCULAR RESISTANCE; MYOPATHY; NEUROMUSCULAR BLOCKING; NUTRITIONAL SUPPORT; OXYGEN CONSUMPTION; OXYGENATION; PARENTERAL NUTRITION; PREVALENCE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; RISK ASSESSMENT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT PLANNING; TUBE FEEDING; UNSPECIFIED SIDE EFFECT; VASODILATATION; WEAKNESS;

EID: 77953307471     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.09-2416     Document Type: Review

References (107)

1. Mercat A, Richard JC, Vielle B, et al; Expiratory Pressure (Express) Study Group. Positive end-expiratory pressure setting in adults with acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. JAMA. 2008;299(6):646-655.
2. Meade MO, Cook DJ, Guyatt GH, et al; Lung Open Ventilation Study Investigators. Ventilation strategy using low tidal volumes, recruitment maneuvers, and high positive end-expiratory pressure for acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. JAMA. 2008;299(6):637-645.
3. Arroliga AC, Thompson BT, Ancukiewicz M, et al; Acute Respiratory Distress Syndrome Network. Use of sedatives, opioids, and neuromuscular blocking agents in patients with acute lung injury and acute respiratory distress syndrome. Crit Care Med. 2008;36(4):1083-1088.
4. Arroliga A, Frutos-Vivar F, Hall J, et al; International Mechanical Ventilation Study Group. Use of sedatives and neuromuscular blockers in a cohort of patients receiving mechanical ventilation. Chest. 2005;128(2):496-506.
5. Sessler CN. Sedation, analgesia, and neuromuscular blockade for high-frequency oscillatory ventilation. Crit Care Med. 2005;33(3 suppl):S209-S216.
6. Sessler CN. Train-of-four to monitor neuromuscular blockade? Chest. 2004;126(4):1018-1022.
7. Gainnier M, Roch A, Forel JM, et al. Effect of neuromuscular blocking agents on gas exchange in patients presenting with acute respiratory distress syndrome. Crit Care Med. 2004;32(1):113-119. (Pubitemid 38125571)
8. Forel JM, Roch A, Marin V, et al. Neuromuscular blocking agents decrease inflammatory response in patients presenting with acute respiratory distress syndrome. Crit Care Med. 2006;34(11):2749-2757. (Pubitemid 44610939)
9. Hansen-Flaschen J, Cowen J, Raps EC. Neuromuscular blockade in the intensive care unit. More than we bargained for. Am Rev Respir Dis. 1993;147(1):234-236.
10. Rossaint R, Falke KJ, López F, Slama K, Pison U, Zapol WM. Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med. 1993;328(6):399-405. (Pubitemid 23042288)
11. Taylor RW, Zimmerman JL, Dellinger RP, et al; Inhaled Nitric Oxide in ARDS Study Group. Low-dose inhaled nitric oxide in patients with acute lung injury: a randomized controlled trial. JAMA. 2004;291(13):1603-1609.
12. Michael JR, Barton RG, Saffle JR, et al. Inhaled nitric oxide versus conventional therapy: effect on oxygenation in ARDS. Am J Respir Crit Care Med. 1998;157(5 pt 1):1372-1380. (Pubitemid 128679361)
13. Dellinger RP, Zimmerman JL, Taylor RW, et al; Inhaled Nitric Oxide in ARDS Study Group. Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome: results of a randomized phase II trial. Crit Care Med. 1998;26(1):15-23.
14. Troncy E, Collet JP, Shapiro S, et al. Inhaled nitric oxide in acute respiratory distress syndrome: a pilot randomized controlled study. Am J Respir Crit Care Med. 1998;157(5 pt 1):1483-1488. (Pubitemid 28242081)
15. Lundin S, Mang H, Smithies M, Stenqvist O, Frostell C; The European Study Group of Inhaled Nitric Oxide. Inhalation of nitric oxide in acute lung injury: results of a European multicentre study. Intensive Care Med. 1999;25(9):911-919.
16. Sokol J, Jacobs SE, Bohn D. Inhaled nitric oxide for acute hypoxemic respiratory failure in children and adults. Cochrane Database Syst Rev. 2003;(1):CD002787.
17. Adhikari NK, Burns KE, Friedrich JO, Granton JT, Cook DJ, Meade MO. Effect of nitric oxide on oxygenation and mortality in acute lung injury: systematic review and meta-analysis. BMJ. 2007;334(7597):779.
18. Hsu CW, Lee DL, Lin SL, Sun SF, Chang HW. The initial response to inhaled nitric oxide treatment for intensive care unit patients with acute respiratory distress syndrome. Respiration. 2008;75(3):288-295.
19. Doering EB, Hanson CW III, Reily DJ, Marshall C, Marshall BE. Improvement in oxygenation by phenylephrine and nitric oxide in patients with adult respiratory distress syndrome. Anesthesiology. 1997;87(1):18-25. (Pubitemid 27438619)
20. Kerins DM, Murray R, FitzGerald GA. Prostacyclin and prostaglandin E1: molecular mechanisms and therapeutic utility. Prog Hemost Thromb. 1991;10:307-337.
21. Lowson SM. Inhaled alternatives to nitric oxide. Crit Care Med. 2005;33(3 suppl):S188-S195.
22. Siobal MS. Pulmonary vasodilators. Respir Care. 2007;52(7):885-899.
23. Siobal M. Aerosolized prostacyclins. Respir Care. 2004;49(6):640-652.
24. Siobal MS, Kallet RH, Pittet JF, et al. Description and evaluation of a delivery system for aerosolized prostacyclin. Respir Care. 2003;48(8):742-753. (Pubitemid 47377822)
25. van Heerden PV, Barden A, Michalopoulos N, Bulsara MK, Roberts BL. Dose-response to inhaled aerosolized prostacyclin for hypoxemia due to ARDS. Chest. 2000;117(3):819-827. (Pubitemid 30152226)
26. Van Heerden PV, Blythe D, Webb SA. Inhaled aerosolized prostacyclin and nitric oxide as selective pulmonary vasodilators in ARDS-a pilot study. Anaesth Intensive Care. 1996;24 (5):564-568. (Pubitemid 26377305)
27. van Heerden PV, Caterina P, Filion P, Spagnolo DV, Gibbs NM. Pulmonary toxicity of inhaled aerosolized prostacyclin therapy-an observational study. Anaesth Intensive Care. 2000;28(2):161-166. (Pubitemid 30201231)
28. Van Heerden PV, Webb SA, Hee G, Corkeron M, Thompson WR. Inhaled aerosolized prostacyclin as a selective pulmonary vasodilator for the treatment of severe hypoxaemia. Anaesth Intensive Care. 1996;24(1):87-90. (Pubitemid 26068721)
29. Pappert D, Busch T, Gerlach H, Lewandowski K, Radermacher P, Rossaint R. Aerosolized prostacyclin versus inhaled nitric oxide in children with severe acute respiratory distress syndrome. Anesthesiology. 1995;82(6):1507-1511.
30. Olschewski H, Rohde B, Behr J, et al. Pharmacodynamics and pharmacokinetics of inhaled iloprost, aerosolized by three different devices, in severe pulmonary hypertension. Chest. 2003;124 (4):1294-1304.
31. Olschewski H, Simonneau G, Galiè N, et al; Aerosolized Iloprost Randomized Study Group. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002;347(5):322-329.
32. Harris KW, O'Riordan TG, Smaldone GC. Aerosolized iloprost customized for the critically ill. Respir Care. 2007;52(11):1507-1509.
33. Voswinckel R, Enke B, Reichenberger F, et al. Favorable effects of inhaled treprostinil in severe pulmonary hypertension: results from randomized controlled pilot studies. J Am Coll Cardiol. 2006;48(8):1672-1681.
34. Meyer J, Theilmeier G, Van Aken H, et al. Inhaled prostaglandin E1 for treatment of acute lung injury in severe multiple organ failure. Anesth Analg. 1998;86(4):753-758.
35. Sood BG, Delaney-Black V, Aranda JV, Shankaran S. Aerosolized PGE1: a selective pulmonary vasodilator in neonatal hypoxemic respiratory failure results of a Phase I/II open label clinical trial. Pediatr Res. 2004;56(4):579-585.
36. Glauser FL, Polatty RC, Sessler CN. Worsening oxygenation in the mechanically ventilated patient. Causes, mechanisms, and early detection. Am Rev Respir Dis. 1988;138(2):458-465.
37. Bencowitz HZ, LeWinter MM, Wagner PD. Effect of sodium nitroprusside on ventilation-perfusion mismatching in heart failure. J Am Coll Cardiol. 1984;4(5):918-922. (Pubitemid 15206639)
38. Miller MJ, Chappell TR, Cook W, De Olazabal JR, Rubin LJ. Effects of oral hydralazine on gas exchange in patients with cor pulmonale. Am J Med. 1983;75(6):937-942. (Pubitemid 14204583)
39. Keller CA, Shepard JW Jr, Chun DS, Dolan GF, Vasquez P, Minh VD. Effects of hydralazine on hemodynamics, ventilation, and gas exchange in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Am Rev Respir Dis. 1984;130(4):606-611. (Pubitemid 15200013)
40. Mookherjee S, Fuleihan D, Warner RA, Vardan S, Obeid AI. Effects of sublingual nitroglycerin on resting pulmonary gas exchange and hemodynamics in man. Circulation. 1978;57(1):106-110. (Pubitemid 8254683)
41. Toraman F, Kopman EA, Calisçirisççi U, et al. Nitroglycerin-induced hypoxemia does not produce myocardial ischemia. J Cardiothorac Vasc Anesth. 1997;11(7):861-863. (Pubitemid 27523091)
42. Melot C, Hallemans R, Naeije R, Mols P, Lejeune P. Deleterious effect of nifedipine on pulmonary gas exchange in chronic obstructive pulmonary disease. Am Rev Respir Dis. 1984;130(4):612-616. (Pubitemid 15200014)
43. Simonneau G, Escourrou P, Duroux P, Lockhart A. Inhibition of hypoxic pulmonary vasoconstriction by nifedipine. N Engl J Med. 1981;304(26):1582-1585. (Pubitemid 11122507)
44. Neely CF, Stein R, Matot I, Batra V, Cheung A. Calcium blockage in pulmonary hypertension and hypoxic vasoconstriction. New Horiz. 1996;4(1):99-106.
45. Graham R, Skoog C, Macedo W, et al. Dopamine, dobutamine, and phentolamine effects on pulmonary vascular mechanics. J Appl Physiol. 1983;54(5):1277-1283.
46. Ward DS, Bellville JW. Effect of intravenous dopamine on hypercapnic ventilatory response in humans. J Appl Physiol. 1983;55(5):1418-1425.
47. Olson LG, Hensley MJ, Saunders NA. Ventilatory responsiveness to hypercapnic hypoxia during dopamine infusion in humans. Am Rev Respir Dis. 1982;126(5):783-787.
48. Van De Borne P, Somers VK. Dopamine and congestive heart failure: pharmacology, clinical use, and precautions. Congest Heart Fail. 1999;5(5):216-221. (Pubitemid 30004157)
49. Radermacher P, Santak B, Wüst HJ, Tarnow J, Falke KJ. Prostacyclin for the treatment of pulmonary hypertension in the adult respiratory distress syndrome: effects on pulmonary capillary pressure and ventilation-perfusion distributions. Anesthesiology. 1990;72(2):238-244. (Pubitemid 20057987)
50. Abraham E, Baughman R, Fletcher E, et al. Liposomal prostaglandin E1 (TLC C-53) in acute respiratory distress syndrome: a controlled, randomized, double-blind, multicenter clinical trial. TLC C-53 ARDS Study Group. Crit Care Med. 1999;27(8):1478-1485.
51. Tai E, Read J. Response of blood gas tensions to aminophylline and isoprenaline in patients with asthma. Thorax. 1967;22(6):543-549.
52. Rodriguez-Roisin R, Bencowitz HZ, Ziegler MG, Wagner PD. Gas exchange responses to bronchodilators following methacholine challenge in dogs. Am Rev Respir Dis. 1984;130(4):617-626. (Pubitemid 15200015)
53. Matthay MA, Brower R, Thompson BT, et al. Randomized, placebo-controlled trial of an aerosolized beta-2 adrenergic agonist (albuterol) for the treatment of acute lung injury [abstract]. Am J Respir Crit Care Med. 2009;179:A2166.
54. Papazian L, Roch A, Bregeon F, et al. Inhaled nitric oxide and vasoconstrictors in acute respiratory distress syndrome. Am J Respir Crit Care Med. 1999;160(2):473-479. (Pubitemid 29380660)
55. Roch A, Papazian L, Bregeon F, et al. High or low doses of almitrine bismesylate in ARDS patients responding to inhaled NO and receiving norepinephrine? Intensive Care Med. 2001;27(11):1737-1743.
56. Langer M, Mascheroni D, Marcolin R, Gattinoni L. The prone position in ARDS patients. A clinical study. Chest. 1988;94(1):103-107.
57. Stocker R, Neff T, Stein S, Ecknauer E, Trentz O, Russi E. Prone postioning and low-volume pressure-limited ventilation improve survival in patients with severe ARDS. Chest. 1997;111(4):1008-1017. (Pubitemid 27171474)
58. Mure M, Martling CR, Lindahl SG. Dramatic effect on oxygenation in patients with severe acute lung insufficiency treated in the prone position. Crit Care Med. 1997;25(9):1539-1544. (Pubitemid 27391484)
59. Chatte G, Sab JM, Dubois JM, Sirodot M, Gaussorgues P, Robert D. Prone position in mechanically ventilated patients with severe acute respiratory failure. Am J Respir Crit Care Med. 1997;155(2):473-478. (Pubitemid 27085788)
60. Pappert D, Rossaint R, Slama K, Grüning T, Falke KJ. Influence of positioning on ventilation-perfusion relationships in severe adult respiratory distress syndrome. Chest. 1994;106(5):1511-1516. (Pubitemid 24346120)
61. Girard TD, Bernard GR. Mechanical ventilation in ARDS: a state-of-the-art review. Chest. 2007;131(3):921-929.
62. Guerin C, Badet M, Rosselli S, et al. Effects of prone position on alveolar recruitment and oxygenation in acute lung injury. Intensive Care Med. 1999;25(11):1222-1230.
63. Mutoh T, Guest RJ, Lamm WJ, Albert RK. Prone position alters the effect of volume overload on regional pleural pressures and improves hypoxemia in pigs in vivo. Am Rev Respir Dis. 1992;146(2):300-306.
64. Albert RK, Hubmayr RD. The prone position eliminates compression of the lungs by the heart. Am J Respir Crit Care Med. 2000;161(5):1660-1665.
65. Lamm WJ, Graham MM, Albert RK. Mechanism by which the prone position improves oxygenation in acute lung injury. Am J Respir Crit Care Med. 1994;150(1):184-193.
66. Albert RK. The prone position in acute respiratory distress syndrome: where we are, and where do we go from here. Crit Care Med. 1997;25(9):1453-1454.
67. Blanch L, Mancebo J, Perez M, et al. Short-term effects of prone position in critically ill patients with acute respiratory distress syndrome. Intensive Care Med. 1997;23(10):1033-1039.
68. Gattinoni L, Tognoni G, Pesenti A, et al; Prone-Supine Study Group. Effect of prone positioning on the survival of patients with acute respiratory failure. N Engl J Med. 2001;345(8):568-573.
69. Guerin C, Gaillard S, Lemasson S, et al. Effects of systematic prone positioning in hypoxemic acute respiratory failure: a randomized controlled trial. JAMA. 2004;292(19):2379-2387.
70. Mancebo J, Fernández R, Blanch L, et al. A multicenter trial of prolonged prone ventilation in severe acute respiratory distress syndrome. Am J Respir Crit Care Med. 2006;173(11):1233-1239.
71. Taccone P, Pesenti A, Latini R, et al; Prone-Supine II Study Group. Prone positioning in patients with moderate and severe acute respiratory distress syndrome: a randomized controlled trial. JAMA. 2009;302(18):1977-1984.
72. The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 2000;342(18):1301- 1308.
73. Alsaghir AH, Martin CM. Effect of prone positioning in patients with acute respiratory distress syndrome: a metaanalysis. Crit Care Med. 2008;36(2):603-609.
74. Schuerer DJ, Kolovos NS, Boyd KV, Coopersmith CM. Extracorporeal membrane oxygenation: current clinical practice, coding, and reimbursement. Chest. 2008;134(1):179-184.
75. Peek GJ, Clemens F, Elbourne D, et al. CESAR: conventional ventilatory support vs extracorporeal membrane oxygenation for severe adult respiratory failure. BMC Health Serv Res. 2006;6:163.
76. Davies A, Jones D, Bailey M, et al; Australia and New Zealand Extracorporeal Membrane Oxygenation (ANZ ECMO) Influenza Investigators. Extracorporeal membrane oxygenation for 2009 influenza A(H1N1) acute respiratory distress syndrome. JAMA. 2009;302(17):1888-1895.
77. Marasco SF, Lukas G, McDonald M, McMillan J, Ihle B. Review of ECMO (extra corporeal membrane oxygenation) support in critically ill adult patients. Heart Lung Circ. 2008;17(Suppl 4):S41-S47.
78. Zapol WM, Snider MT, Hill JD, et al. Extracorporeal membrane oxygenation in severe acute respiratory failure. A randomized prospective study. JAMA. 1979;242(20):2193-2196.
79. Morris AH, Wallace CJ, Menlove RL, et al. Randomized clinical trial of pressure-controlled inverse ratio ventilation and extracorporeal CO2 removal for adult respiratory distress syndrome. Am J Respir Crit Care Med. 1994;149(2 pt 1):295-305.
80. Peek GJ, Mugford M, Tiruvoipati R, et al; CESAR trial collaboration. Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial. Lancet. 2009;374(9698):1351- 1363.
81. Kolla S, Awad SS, Rich PB, Schreiner RJ, Hirschl RB, Bartlett RH. Extracorporeal life support for 100 adult patients with severe respiratory failure. Ann Surg. 1997;226(4):544-564.
82. Hemmila MR, Rowe SA, Boules TN, et al. Extracorporeal life support for severe acute respiratory distress syndrome in adults. Ann Surg. 2004;240(4):595-605.
83. Iglesias M, Jungebluth P, Petit C, et al. Extracorporeal lung membrane provides better lung protection than conventional treatment for severe postpneumonectomy noncardiogenic acute respiratory distress syndrome. J Thorac Cardiovasc Surg. 2008;135(6):1362-1371.
84. Nehra D, Goldstein AM, Doody DP, Ryan DP, Chang Y, Masiakos PT. Extracorporeal membrane oxygenation for nonneonatal acute respiratory failure: the Massachusetts General Hospital experience from 1990 to 2008. Arch Surg. 2009;144(5):427-432., discussion 432.
85. Kopp R, Dembinski R, Kuhlen R. Role of extracorporeal lung assist in the treatment of acute respiratory failure. Minerva Anestesiol. 2006;72(6):587-595. (Pubitemid 43918800)
86. Bein T, Weber F, Philipp A, et al. A new pumpless extracorporeal interventional lung assist in critical hypoxemia/hypercapnia. Crit Care Med. 2006;34(5):1372-1377.
87. Mielck F, Quintel M. Extracorporeal membrane oxygenation. Curr Opin Crit Care. 2005;11(1):87-93.
88. Groeneveld AB. Vascular pharmacology of acute lung injury and acute respiratory distress syndrome. Vascul Pharmacol. 2002;39(4-5):247-256.
89. Arif SK, Verheij J, Groeneveld AB, Raijmakers PG. Hypoproteinemia as a marker of acute respiratory distress syndrome in critically ill patients with pulmonary edema. Intensive Care Med. 2002;28(3):310-317.
90. Wiedemann HP, Wheeler AP, Bernard GR, et al; National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Comparison of two fluid-management strategies in acute lung injury. N Engl J Med. 2006;354(24):2564-2575.
91. Calfee CS, Matthay MA. Nonventilatory treatments for acute lung injury and ARDS. Chest. 2007;131(3):913-920.
92. Mitchell JP, Schuller D, Calandrino FS, Schuster DP. Improved outcome based on fluid management in critically ill patients requiring pulmonary artery catheterization. Am Rev Respir Dis. 1992;145(5):990-998.
93. Simmons RS, Berdine GG, Seidenfeld JJ, et al. Fluid balance and the adult respiratory distress syndrome. Am Rev Respir Dis. 1987;135(4):924-929. (Pubitemid 17055525)
94. Martin GS, Mangialardi RJ, Wheeler AP, Dupont WD, Morris JA, Bernard GR. Albumin and furosemide therapy in hypoproteinemic patients with acute lung injury. Crit Care Med. 2002;30(10):2175-2182. (Pubitemid 35191564)
95. Martin GS, Moss M, Wheeler AP, Mealer M, Morris JA, Bernard GR. A randomized, controlled trial of furosemide with or without albumin in hypoproteinemic patients with acute lung injury. Crit Care Med. 2005;33(8):1681-1687.
96. Finfer S, Bellomo R, Boyce N, French J, Myburgh J, Norton R; SAFE Study Investigators. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med. 2004;350(22):2247-2256. (Pubitemid 38669207)
97. Schuster KM, Alouidor R, Barquist ES. Nonventilatory interventions in the acute respiratory distress syndrome. J Intensive Care Med. 2008;23(1):19-32.
98. Meduri GU, Headley AS, Golden E, et al. Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial. JAMA. 1998;280(2):159-165.
99. Steinberg KP, Hudson LD, Goodman RB, et al; National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med. 2006;354(16):1671-1684.
100. Meduri GU, Golden E, Freire AX, et al. Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial. Chest. 2007;131(4):954-963.
101. Tang BM, Craig JC, Eslick GD, Seppelt I, McLean AS. Use of corticosteroids in acute lung injury and acute respiratory distress syndrome: a systematic review and meta-analysis. Crit Care Med. 2009;37(5):1594-1603.
102. Marik PE, Pastores SM, Annane D, et al; American College of Critical Care Medicine. Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: consensus statements from an international task force by the American College of Critical Care Medicine. Crit Care Med. 2008;36(6):1937-1949.
103. Gadek JE, DeMichele SJ, Karlstad MD, et al; Enteral Nutrition in ARDS Study Group. Effect of enteral feeding with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants in patients with acute respiratory distress syndrome. Crit Care Med. 1999;27(8):1409-1420.
104. Pontes-Arruda A, Aragão AM, Albuquerque JD. Effects of enteral feeding with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants in mechanically ventilated patients with severe sepsis and septic shock. Crit Care Med. 2006;34(9):2325-2333.
105. Singer P, Theilla M, Fisher H, Gibstein L, Grozovski E, Cohen J. Benefit of an enteral diet enriched with eicosapentaenoic acid and gamma-linolenic acid in ventilated patients with acute lung injury. Crit Care Med. 2006;34(4):1033-1038.
106. Pontes-Arruda A, Demichele S, Seth A, Singer P. The use of an inflammation-modulating diet in patients with acute lung injury or acute respiratory distress syndrome: a meta-analysis of outcome data. JPEN J Parenter Enteral Nutr. 2008;32(6):596-605.
107. Sabater J, Masclans JR, Sacanell J, Chacon P, Sabin P, Planas M. Effects on hemodynamics and gas exchange of omega-3 fatty acid-enriched lipid emulsion in acute respiratory distress syndrome (ARDS): a prospective, randomized, double-blind, parallel group study. Lipids Health Dis. 2008;7:39.